Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Inflammation of the glomeruli characterized by deposits at the intraglomerular mesangium, resulting in thickening of the glomerular basement membrane, activation of complement, and impaired kidney function secondary to damaged glomeruli.
Biomarker and diagnostic research for membranoproliferative glomerulonephritis has been reported in the published literature.
9 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE4, 2 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04183101](https://clinicaltrials.gov/study/NCT04183101) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 1:42 AM UTC
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy |
PHASE2 |
Region Skane |
RECRUITING |
[NCT06065852](https://clinicaltrials.gov/study/NCT06065852) | National Registry of Rare Kidney Diseases | — | UK Kidney Association | RECRUITING |
[NCT05985122](https://clinicaltrials.gov/study/NCT05985122) | New Analytic Tools for aHUS and C3G Diagnosis | NA | Mario Negri Institute for Pharmacological Research | ACTIVE_NOT_RECRUITING |
[NCT03955445](https://clinicaltrials.gov/study/NCT03955445) | Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN | PHASE3 | Novartis Pharmaceuticals | RECRUITING |
[NCT04572854](https://clinicaltrials.gov/study/NCT04572854) | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | PHASE2 | Apellis Pharmaceuticals, Inc. | UNKNOWN |
199 publications have been identified in PubMed for membranoproliferative glomerulonephritis. Kisho has analyzed 100 by research type. Research spans Case Report / Case Series (46%), Review / Meta-Analysis (28%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 46 | 46% |
Research summaries | 28 | 28% |
Disease patterns and progression | 15 | 15% |
Clinical study results | 4 | 4% |
Testing and diagnosis research | 3 | 3% |
Laboratory research | 2 | 2% |
Other research | 1 | 1% |
New treatment approaches | 1 | 1% |
Vinogradova EV (2026). [PMID: 41589396](https://pubmed.ncbi.nlm.nih.gov/41589396/). *Animal Model Exp Med*. [Basic Science / Preclinical]
Benigni A (2026). [PMID: 41076080](https://pubmed.ncbi.nlm.nih.gov/41076080/). *Kidney Int*. [Basic Science / Preclinical]
Nakao Y (2026). [PMID: 40634092](https://pubmed.ncbi.nlm.nih.gov/40634092/). *Internal medicine (Tokyo, Japan)*. [Case Report / Case Series]
Filippone EJ (2026). [PMID: 41767602](https://pubmed.ncbi.nlm.nih.gov/41767602/). *Front Nephrol*. [Review / Meta-Analysis]
Dixit S (2026). [PMID: 41208293](https://pubmed.ncbi.nlm.nih.gov/41208293/). *Current opinion in nephrology and hypertension*. [Review / Meta-Analysis]
Caravaca-Fontán F (2026). [PMID: 41502799](https://pubmed.ncbi.nlm.nih.gov/41502799/). *Kidney Int Rep*. [Review / Meta-Analysis]
Román Ortiz E (2026). [PMID: 41361594](https://pubmed.ncbi.nlm.nih.gov/41361594/). *Pediatr Nephrol*. [Case Report / Case Series]
Pontes IBS (2026). [PMID: 41105855](https://pubmed.ncbi.nlm.nih.gov/41105855/). *J Bras Nefrol*. [Review / Meta-Analysis]
Kavanagh D (2026). [PMID: 41541782](https://pubmed.ncbi.nlm.nih.gov/41541782/). *Kidney Int Rep*. [Review / Meta-Analysis]
Li H (2026). [PMID: 41764449](https://pubmed.ncbi.nlm.nih.gov/41764449/). *BMC Nephrol*. [Case Report / Case Series]
AI-curated news mentioning membranoproliferative glomerulonephritis
Updated Aug 3, 2026
A recent case report details a unique presentation of immune-complex-mediated membranoproliferative glomerulonephritis with linear IgG staining, which resembles atypical anti-glomerular basement membrane disease. This finding may provide insights into the pathophysiology and diagnosis of related kidney disorders.